PanOph

Limbal Stem Cell Deficiency (LSCD)

Cornea

1. Clinical Analogy & Conceptual Foundation

Exam pearl
  • Clinical Analogy: Imagine the corneal surface as a carefully tended garden. The limbal stem cells are the gardeners - they continuously plant new cells (corneal epithelium) that maintain the transparent, healthy surface. When the gardeners are lost (LSCD), weeds (conjunctival epithelium and goblet cells) invade the garden, the soil erodes (stromal scarring), and the garden loses its clarity. Restoring vision means re-establishing the gardeners - either by transplanting them from a healthy plot on the same patient, a family donor, or cultivating them in a laboratory.

Key Conceptual Points

  • Limbal stem cell deficiency (LSCD) is an ocular surface disease caused by genetic defects or secondary insults to limbal epithelial stem cells (LESCs) and their niche.
  • The corneal epithelium is maintained by limbal epithelial stem/progenitor cells. Loss leads to conjunctivalization, neovascularization, ocular-surface inflammation, scarring, and decreased vision.
  • Limbal stem cell deficiency (LSCD) is treatable; in selected cases, medical treatment or limbal stem cell transplantation (LSCT) can restore the corneal epithelial phenotype. Limbal stem cell transplantation (LSCT) and cell-based therapies have advanced ocular-surface rehabilitation for limbal stem cell deficiency (LSCD).
  • Understanding limbal stem cell deficiency (LSCD) is fundamental to corneal surgery, transplantation immunology, and regenerative ophthalmology.

2. Anatomy of the Limbal Niche

The Corneoscleral Limbus - Structural Overview

  • The limbus is a 1–2 mm transitional zone between the avascular cornea and the vascularized conjunctiva/episclera.
  • It is the exclusive anatomical home of the limbal epithelial stem cells (LESCs).

Palisades of Vogt (POV)

  • The palisades of Vogt (POV) are radially oriented, finger-like stromal ridges at the superior and inferior limbus, representing the microarchitecture of the limbal niche.
  • They may be assessed clinically by slit-lamp biomicroscopy; fluorescein staining highlights epithelial abnormality in limbal stem cell deficiency (LSCD) rather than the palisades of Vogt (POV) themselves.
FeatureDetail
Location• Superior and inferior limbus (most prominent) • Less prominent nasally and temporally
Structure• Radially oriented fibrovascular stromal ridges projecting upward into the multilayered limbal epithelium
Function• House limbal epithelial stem cells in the basal epithelial layer • Provide a niche microenvironment
Clinical Relevance• Loss or flattening of the palisades of Vogt may be associated with limbal stem cell deficiency but is not pathognomonic • Corneal conjunctivalization is the defining clinical feature • Visualized by slit-lamp examination and in vivo confocal microscopy
Vascularity• Rich capillary network • The specific oxygen, nutrient, and cytokine-delivery functions for limbal epithelial stem cells remain incompletely established
Melanocytes• Present • A specific ultraviolet-protective effect for limbal epithelial stem cells was not established by the available evidence
Basement membrane• Provides a structural scaffold • The precise contribution of laminin, fibronectin, and collagen IV remains incompletely verified here
Stromal keratocytes• Limbal fibroblasts or stromal niche cells produce paracrine epithelial mitogens, including keratinocyte growth factor (KGF) • Hepatocyte growth factor (HGF) expression differs between limbal and corneal fibroblasts • The cited evidence does not establish epidermal growth factor (EGF) secretion by stromal keratocytes or maintenance of limbal epithelial stem-cell quiescence
Melanocytes• Limbal melanocytes support limbal epithelial stem/progenitor-cell maintenance in human two-dimensional and three-dimensional models • A specific ultraviolet-protective effect was not established by the available evidence • Stem cell factor (SCF)/KIT receptor (KIT) signaling contributes to the limbal niche and limbal epithelial stem-cell survival • Direct regulation through stem cell factor/KIT signaling by melanocytes specifically is not established
Panstromal immune cells• Forkhead box P3 (Foxp3)-positive regulatory T cells have been identified within the corneal epithelium near or colocalized with limbal stem cells in a mouse model • They may contribute to epithelial wound healing • Their role in maintaining limbal immune privilege is not yet established
Vascular endothelium• The limbal microvascular network supports limbal epithelial stem-cell survival, proliferation, and maintenance of stemness within the niche • Specific nutrient-delivery and angiocrine-signaling functions within the human limbal niche remain incompletely defined
Extracellular matrix• Contains fibronectin and tenascin and contributes to the specialized limbal stem-cell niche • Extracellular-matrix interactions can regulate limbal epithelial stem-cell adhesion and signaling • The specific independent effects of fibronectin and tenascin on these processes are not fully established
Nerve fibres• Nerve growth factor (NGF) signaling supports limbal epithelial progenitor-cell proliferation, colony-forming efficiency, and maintenance of the stem-cell phenotype in human limbal-cell culture • Substance P has context-dependent effects and should not be described unconditionally as maintaining limbal epithelial stem-cell survival • Excessive substance P signaling may aggravate stem-cell deficiency through mechanistic target of rapamycin (mTOR)-associated senescence

3. Stem Cell Biology & Corneal Epithelial Renewal

The XYZ Hypothesis of Corneal Epithelial Maintenance (Thoft & Friend, 1983)

Exam pearl
  • XYZ Equation: X (proliferation and anterior migration of basal epithelial cells) + Y (centripetal migration of peripheral/limbal cells) = Z (loss of superficial cells by desquamation).
  • In limbal stem cell deficiency (LSCD), loss or dysfunction of limbal stem cells and/or their niche disrupts the limbal contribution to epithelial renewal and impairs effective centripetal migration; complete abolition of migration is not universal.
  • Residual basal/transient-amplifying-cell proliferation may provide limited or temporary compensation, but loss or dysfunction of limbal epithelial stem cells (LESCs) generally makes epithelial renewal insufficient to sustain normal corneal epithelial homeostasis.
  • Loss or dysfunction of limbal stem cells and/or their niche can make effective epithelial renewal insufficient to balance ongoing surface-cell loss (Z), resulting in impaired wound healing, recurrent epithelial defects, and progressive conjunctivalization or epithelial breakdown.

LESC Properties & Markers

Property / MarkerDetailsClinical / Research Relevance
Slow-cycling / quiescent• Low mitotic activity • Bromodeoxyuridine (BrdU) label-retaining• Associated with relative resistance of limbal epithelium to 5-fluorouracil toxicity
ATP-binding cassette subfamily G member 2 (ABCG2)• ATP-binding cassette transporter / efflux pump • Expressed in limbal basal cells • Enriched in Hoechst side-population cells• Associated with greater clonogenic or stem-cell-associated properties • Drug resistance of limbal epithelial stem cells (LESCs) themselves is not established by the cited primary study
N-cadherin• Cell-cell adhesion molecule • Expressed in basal limbal putative stem/progenitor cells • Expression decreases with proliferation• May help enrich or distinguish putative limbal epithelial stem/progenitor populations from more proliferative cells • Not a definitive limbal epithelial stem-cell-versus-transient-amplifying-cell marker
Vimentin• Intermediate filament • Demonstrated in basal limbal epithelial cells• Useful immunohistochemical phenotype marker • Not specific for limbal epithelial stem cells because it is also expressed by stromal and other non-epithelial cells
Absence of cytokeratin 3/cytokeratin 12 (CK3/CK12)• Differentiation-associated corneal epithelial markers are generally low or absent in undifferentiated limbal stem/progenitor-cell populations• Cytokeratin 3 (CK3) positivity is compatible with corneal epithelial differentiation • Cytokeratin 3 (CK3) positivity alone does not establish that a cell is specifically a transient-amplifying cell
Absence of cytokeratin 19 (CK19)• Cytokeratin 19 (CK19) is expressed in conjunctival epithelium • Cytokeratin 19 (CK19) is not absent from all limbal stem/progenitor-cell populations• Cytokeratin 19 (CK19) on the corneal surface supports conjunctivalization or limbal stem cell deficiency (LSCD) in the appropriate clinical context • Cytokeratin 19 (CK19), in isolation, is not proof of conjunctivalization
Nestin• Reported in limbal epithelial side-population cells • Also reported in limbal niche/stromal cells • Expression is population- and method-dependent• Not a specific limbal epithelial stem-cell marker • Expression does not by itself establish a shared neural crest lineage
p63-bright (ΔNp63α)• Nuclear transcription factor • Commonly associated with the ΔNp63α isoform • Useful marker of limbal epithelial stem/progenitor-cell content• Culture-quality and outcome-associated measure for cultivated limbal epithelial transplantation (CLET) • Commonly assessed in cultured cells by immunostaining or related phenotyping • Prospective flow-cytometric selection of limbal epithelial stem cells based on p63 is not established

Centripetal Migration - The Conveyor Belt

  • Limbal epithelial stem cells (LESCs) divide asymmetrically: one daughter cell remains as a limbal epithelial stem cell (LESC) (self-renewal), the other becomes a transient amplifying cell (TAC).
  • Transient amplifying cells (TACs) migrate centripetally across the cornea, terminally differentiating into post-mitotic cells (PMCs) and finally terminally differentiated cells (TDCs) at the surface.
  • The entire corneal epithelium turns over every 7–10 days.
Cell TypeLocationProliferative CapacityMarkers
Limbal epithelial stem cell (LESC)Limbal basal epitheliumHigh • Asymmetric divisionPutative markers • Tumor protein p63-bright (p63bright) • ATP-binding cassette subfamily G member 2 (ABCG2) • N-cadherin • Cytokeratin 3-negative (CK3−) • No definitive marker profile
Transient amplifying cell (TAC)Peripheral cornea • Migrating centrallyLimited • Finite number of divisionsNo definitive marker profile • Tumor protein p63 (p63) expression may be retained during early differentiation • Cytokeratin 3 (CK3) expression is acquired with differentiation
Post-mitotic cell (PMC)Suprabasal corneaNoneCytokeratin 3-positive (CK3+) • Cytokeratin 12-positive (CK12+)
Terminally differentiated cell (TDC)Superficial epitheliumNone • DesquamateCytokeratin 3-positive (CK3+) • Cytokeratin 12-positive (CK12+) • Mucin 16-positive (MUC16+)

4. Etiology & Classification

Primary vs Secondary limbal stem cell deficiency (LSCD)

A. PRIMARY LSCD - Intrinsic/Genetic Niche Defect
A. PRIMARY LSCD - Intrinsic/Genetic Niche Defect
ConditionMechanism of limbal stem cell deficiency (LSCD)
• Aniridia (PAX6 mutation)• Defective limbal epithelial stem cell (LESC) specification/maintenance • PAX6 haploinsufficiency causes progressive corneal conjunctivalization
• Keratitis Ichthyosis Deafness (KID) syndrome• GJB2 (Connexin 26) mutation • Generalized ectodermal disturbance with limbal epithelial stem cell deficiency
• Ectrodactyly-Ectodermal Dysplasia-Clefting (EEC)• TP63 mutation • Impaired limbal-cell migration, corneal differentiation, and wound healing causes progressive limbal stem cell deficiency (LSCD)
• Congenital erythrokeratoderma• Rare; primary corneal epithelial stem cell dysfunction
• Dyskeratosis congenita• Telomere shortening • Premature limbal epithelial stem cell (LESC) senescence
• Xeroderma pigmentosum• DNA repair defect • Ultraviolet-induced limbal epithelial stem cell (LESC) apoptosis
• Comel-Netherton syndrome• SPINK5 mutation • Skin/ocular surface inflammation
B. SECONDARY LSCD - Acquired Niche Destruction
B. SECONDARY LSCD - Acquired Niche Destruction
CategoryExamplesBilateral?
CategoryExamplesBilateral?
Chemical/Thermal Burns• Alkali (lime, ammonia) generally causes more severe limbal injury than acid burns. • Thermal injury can also damage limbal stem cells and their niche.• Laterality depends on the exposure. • Not intrinsically bilateral.
Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis• Immune-mediated. • Ocular-surface scarring with limbal stem cell deficiency.• Usually bilateral. • Not invariably bilateral.
Ocular Cicatricial Pemphigoid• Autoimmune; chronic cicatrizing inflammation. • Subconjunctival fibrosis with progressive limbal stem cell loss.• Usually bilateral. • May initially be unilateral or asymmetric.
Chronic Contact Lens Wear• Hypoxic, mechanical, and toxic insults to the limbus. • Often reversible after contact-lens discontinuation when residual limbal stem cells remain.• Laterality and severity vary. • Not uniformly mild or moderate.
Iatrogenic• Limbal surgery, including extensive pterygium or ocular-surface tumor excision. • Antimetabolite exposure such as mitomycin C.• Often sectoral or unilateral.
Neurotrophic Keratopathy• Corneal denervation with reduced trophic signaling, including substance P and nerve growth factor, may impair limbal epithelial stem-cell function.• Laterality depends on the cause.
Radiotherapy• Radiation-associated limbal injury with possible limbal stem-cell loss.• Laterality depends on the irradiated field and dose.
Tumors• Squamous cell carcinoma or extensive ocular-surface squamous neoplasia involving the limbus can cause limbal stem cell deficiency, particularly through extensive limbal involvement or excision.• Generally unilateral.
Peripheral Ulcerative Keratitis• Peripheral inflammatory keratitis can damage the limbal stroma and niche, impairing limbal stem-cell support.• Laterality depends on the underlying inflammatory disease.
Rosacea / Atopy• Chronic or severe ocular rosacea or atopic keratoconjunctivitis. • Chronic inflammation and mechanical trauma may impair limbal stem-cell function.• Laterality and severity vary. • Disease is not uniformly mild.
Multiple Surgeries / Chronic Infections• Multiple limbal or ocular-surface surgeries can cause acquired limbal stem cell deficiency. • Trachoma, herpes simplex virus keratitis, and varicella-zoster virus keratitis can damage the limbal niche or impair limbal stem-cell function.• Laterality is variable and depends on the infection or surgical exposure.
Exam pearl
  • Exam Trap: Alkali burns cause MORE severe limbal stem cell deficiency (LSCD) than acid burns because alkali (high pH) causes liquefactive necrosis, penetrating deeply to destroy the limbal stroma and limbal epithelial stem cell (LESC) niche.
  • Acid causes coagulative necrosis - this self-limits penetration.
  • EXCEPTION: Hydrofluoric acid behaves like alkali - it penetrates deeply.

5. Pathophysiology of LSCD

Sequential Cascade of LSCD

ProcessMechanism/Consequence
LESC Depletion• Primary insult destroys or reduces limbal epithelial stem cells (LESCs) below critical threshold
Loss of Epithelial Barrier• Tight junctions disrupted → epithelial defects • recurrent erosions
Conjunctivalization• Conjunctival epithelium (cytokeratin 19 [CK19]-positive, mucin 5AC [MUC5AC]-positive, with goblet cells) • migrates centripetally over cornea
Neovascularization• Vascular endothelial growth factor A (VEGF-A) upregulation → superficial and deep vessel ingrowth • ends corneal immune privilege
Chronic Inflammation• Inflammatory-cell or cluster of differentiation 4-positive (CD4-positive) T-cell infiltration; interleukin-1 beta and tumor necrosis factor alpha can impair limbal epithelial stem-cell function • Disruption of limbal niche function can compromise corneal immune privilege and promote further inflammation
Stromal Scarring• Chronic epithelial instability and fibrovascular pannus contribute to stromal haze, scarring, and eventual opacification
Tear Film Instability• Goblet cell metaplasia alters mucin layer • poor surface wetting
Visual Loss• Irregular corneal epithelium or surface, stromal scarring, and corneal opacity reduce visual function • Severe or total LSCD may lead to functional blindness

The Role of MUC5AC in Conjunctivalization

  • In normal corneal epithelium: Mucin 5AC (MUC5AC; gel-forming secretory mucin from conjunctival goblet cells) is absent.
  • In limbal stem cell deficiency (LSCD): Mucin 5AC (MUC5AC) transcript can be detected in corneal impression-cytology samples by reverse-transcription polymerase chain reaction and is more sensitive than conventional periodic acid–Schiff–hematoxylin goblet-cell detection.
  • This precedes clinical signs by months.
Molecular Mechanism: Key Mechanism - Paired box 6 (PAX6) in aniridia-related limbal stem cell deficiency (LSCD)
  • Paired box 6 (PAX6) is expressed in limbal epithelial cells, including many basal epithelial cells, although some basal niche cells are paired box 6 (PAX6)-negative.
  • Paired box 6 (PAX6) haploinsufficiency disrupts limbal epithelial stem-cell specification and differentiation and can permit conjunctivalization of the cornea.
  • Paired box 6 (PAX6) regulates corneal-specific keratins, including cytokeratin 3 (CK3) and cytokeratin 12 (CK12).
  • In paired box 6 (PAX6)-haploinsufficient models, abnormal or delayed corneal epithelial differentiation can occur independently of, or before, overt limbal stem cell deficiency; the precise timing and relationship in human aniridia remain uncertain.

6. Clinical Features & Grading (ICCR 2019)

Symptoms

  • Ocular surface discomfort: Irritation, photophobia, foreign body sensation - may be debilitating
  • Recurrent erosions: Persistent and/or recurrent epithelial defects
  • Reduced vision: From epithelial irregularity and haze; later from corneal stromal scarring and opacification
  • Redness: Chronic conjunctival redness; advanced disease may show superficial corneal vascularization, fibrovascular pannus, and stromal neovascularization
  • Conjunctivalization: Goblet cells may be detected on the corneal surface

Signs - Slit-Lamp Examination

Whorl (Vortex) Epitheliopathy - characteristic

  • The whorled pattern represents abnormal epithelium spreading in a spiral pattern from the limbus onto the cornea.
  • It is best seen with fluorescein and a cobalt blue filter.
  • This fluorescein staining pattern supports limbal stem cell deficiency (LSCD) but is not pathognomonic; confirmatory diagnostic testing is recommended when available.
Clinical SignMechanismSignificance
Loss of Palisades of Vogt• Alteration of limbal niche architecture• May be seen in limbal stem cell deficiency • Not a standalone diagnostic marker
Superficial neovascularization• May occur with limbal stem cell deficiency• Not specific to limbal stem cell deficiency
Deep stromal vascularization• May occur in advanced limbal stem cell deficiency• The stated stromal-involvement and transplantation-prognosis conclusions require separate evidence
Whorl/vortex epitheliopathy• Abnormal centripetal migration pattern• Characteristic of limbal stem cell deficiency in the appropriate clinical context • Not independently diagnostic
Persistent epithelial defects• Impaired corneal epithelial homeostasis• Indicates severe/active limbal stem cell deficiency
Pannus formation• Fibrovascular tissue over the cornea• Feature of advanced limbal stem cell deficiency
Symblepharon• Adhesion between bulbar and palpebral conjunctiva• Severe cicatrizing ocular-surface disease, including Stevens–Johnson syndrome, mucous membrane pemphigoid, and chemical burns
Conjunctivalization• Conjunctival epithelium covers the cornea• A defining feature of limbal stem cell deficiency • Cytokeratin 19 is not a specific standalone marker
Corneal opacity / scarring• Corneal stromal scarring and opacity may occur in advanced limbal stem cell deficiency• Treatment, including keratoprosthesis, depends on the overall ocular-surface disease and visual rehabilitation context
Tear film instability• Tear-system abnormalities or tear deficiency may accompany limbal stem cell deficiency • Goblet cells on the cornea indicate conjunctivalization • Destruction of conjunctival goblet cells can contribute to mucin deficiency• Short tear-film break-up time and irregular mires are nonspecific findings

Staging of Limbal Stem Cell Deficiency (LSCD)

StageCorneal involvementLimbal involvement
Stage I• Central 5 mm of cornea remains normal• A: <50% limbal involvement • B: ≥50% but <100% limbal involvement • C: 100% limbal involvement
Stage II• Central 5 mm of cornea is affected• A: <50% limbal involvement • B: ≥50% but <100% limbal involvement
Stage III• Entire corneal surface is affected• No limbal involvement subgroup

7. Investigations & Imaging

A. Impression Cytology (IC) - GOLD STANDARD Clinical Test

  • Impression cytology uses cellulose acetate, nitrocellulose acetate, or hydrophilic polytetrafluoroethylene (Biopore) filter membrane to non-invasively sample the superficial corneal epithelium in limbal stem cell deficiency (LSCD).
MarkerNormal CorneaLimbal Stem Cell Deficiency (LSCD) CorneaSignificance
Cytokeratin 3 (CK3) / Cytokeratin 12 (CK12)• Cytokeratin 12 (CK12) positive in normal cornea• Cytokeratin 12 (CK12) reduced or absent centrally• Loss of corneal epithelial differentiation
Cytokeratin 19 (CK19)• May be detected in corneal epithelium• May be present• Conjunctivalization marker • Cytokeratin 13 (CK13) is more specific than cytokeratin 19 (CK19)
Mucin 5AC (MUC5AC)• Absent• Present• Goblet-cell metaplasia on the cornea
Goblet cells• Absent• Present; periodic acid–Schiff-positive (PAS-positive)• Supports conjunctivalization • Hallmark of limbal stem cell deficiency (LSCD), but not sufficiently sensitive to be considered pathognomonic
Cell morphology• Polygonal, cytokeratin 3 (CK3)-positive• Conjunctival epithelial cells, which may include mucin-producing goblet cells• Epithelial morphology alone may not reliably distinguish epithelial origin
p63-bright cells• Present at limbus• Absent or markedly reduced• Limbal epithelial stem-cell depletion marker
B. In Vivo Confocal Microscopy (IVCM)
B. In Vivo Confocal Microscopy (IVCM)
ParameterFinding in LSCD
Palisades of Vogt• Absent or atrophic palisades of Vogt
Epithelial morphology• Enlarged, irregular epithelial cells with prominent hyperreflective nuclei and indistinct borders • Conjunctival-type epithelium in late disease
Goblet cells• Large oval hyperreflective cells • Presence on the cornea confirms conjunctivalization
Sub-basal nerve plexus• Reduced density or absent • Correlates with limbal stem cell deficiency severity
Langerhans cells (LC)• Increased density - inflammatory activity marker
Stromal keratocytes• Activated (spindle-shaped, hyperreflective) in inflamed stroma
Vascular structures• Superficial neovascularization
Exam pearl
  • Allows real-time, in vivo assessment of limbal niche integrity without biopsy.
  • Loss of the characteristic palisades of Vogt pattern on in vivo confocal microscopy is suggestive of limbal stem cell deficiency but is not diagnostic in isolation.
  • Palisades of Vogt may also be absent or flattened with age.
  • In vivo confocal microscopy provides information about disease severity and can be used for diagnosis and monitoring of limbal stem cell deficiency.

C. Anterior Segment Optical Coherence Tomography (AS-OCT)

FindingInterpretation
Epithelial irregularity/thinning• Supports limbal stem cell deficiency diagnosis or severity assessment • Corresponds to areas of stippled fluorescein staining, whorl-like staining, or pooling
Subepithelial fibrosis / pannus• Fibrovascular tissue • Assess depth and associated stromal opacity for severity and surgical planning
Epithelial thickness mapping• Supports diagnosis and staging assessment
Depth and extent of vascularization• Supports severity assessment and surgical planning • Does not alone determine limbal stem cell transplantation (LSCT) versus keratoprosthesis (KPro)
Palisades of Vogt and limbal crypts• Supports assessment of limbal niche architecture

D. Other Investigations

  • Fluorescein + Rose Bengal staining: Delineates epithelial defects; devitalized cells stain with Rose Bengal
  • Vital dye staining (lissamine green): Comparable ocular-surface staining to Rose Bengal; better tolerated
  • Corneal topography / aberrometry: Documents corneal irregularity and irregular astigmatism; may assist visual assessment and follow-up, but is not a standalone validated measure of limbal stem cell deficiency progression
  • Corneal esthesiometry: Reduced sensation = neurotrophic component (Cochet-Bonnet)
  • Schirmer test / tear-film breakup time: Assesses aqueous tear production and tear-film stability; tear-film dysfunction may coexist and affect ocular-surface management
  • Human leukocyte antigen (HLA) typing: Consider for donor–recipient assessment before allogeneic limbal stem-cell transplantation; matching at human leukocyte antigen-A (HLA-A), human leukocyte antigen-B (HLA-B), and human leukocyte antigen-DR (HLA-DR) may be used in selected living-related donor protocols
  • Systemic workup: Etiology-directed evaluation; when ocular cicatricial pemphigoid is suspected, conjunctival biopsy with immunopathology can support diagnosis; consider genetic evaluation when a congenital syndrome such as aniridia or ectodermal dysplasia–ectrodactyly–cleft syndrome is suspected

8. Staging & Severity

Staging & Severity - Comprehensive Table
Staging & Severity - Comprehensive Table
ParameterStage IStage IIStage III
Limbal involvement• Stage I-A: <50% limbal involvement • Stage I-B: ≥50% but <100% limbal involvement • Stage I-C: 100% limbal involvement• Stage II-A: <50% limbal involvement • Stage II-B: ≥50% but <100% limbal involvement• Entire corneal surface affected
Central cornea• Normal corneal epithelium within the central 5-mm zone• Central 5-mm corneal zone affected• Entire corneal surface affected
Neovascularization• May occur • Not a consensus stage-defining criterion• May occur • Not a consensus stage-defining criterion• Fibrovascular pannus and neovascularization may occur in advanced disease • Not a consensus stage-defining criterion
Epithelial defects• Not a consensus stage-defining criterion• Not a consensus stage-defining criterion• Persistent epithelial defect (PED) and/or recurrent epithelial defects may occur in advanced limbal stem cell deficiency • Not a consensus stage-defining criterion
Goblet cells on cornea• Corneal goblet cells support conjunctivalization • Not a consensus stage-defining criterion• Corneal goblet cells support conjunctivalization • Not a consensus stage-defining criterion• Corneal goblet cells support conjunctivalization • Not a consensus stage-defining criterion
In vivo confocal microscopy (IVCM) - epithelial architecture• In vivo confocal microscopy (IVCM) supports diagnosis and monitoring • Not a consensus stage-defining criterion• In vivo confocal microscopy (IVCM) supports diagnosis and monitoring • Not a consensus stage-defining criterion• Abnormal epithelial morphology and epithelial thinning may occur • In vivo confocal microscopy (IVCM) supports diagnosis and monitoring • Not a consensus stage-defining criterion
Symblepharon• Not a consensus stage-defining criterion• Not a consensus stage-defining criterion• May accompany ocular-surface disorders associated with limbal stem cell deficiency • Not a consensus stage-defining criterion
Stromal scarring• Not a consensus stage-defining criterion• Not a consensus stage-defining criterion• Corneal stromal scarring may occur in advanced disease • Not a consensus stage-defining criterion
Sub-basal nerve plexus• Not a consensus stage-defining criterion• Reduction may be seen in limbal stem cell deficiency • Not a consensus stage-defining criterion• Fragmentation and decreased nerve density may occur, particularly in severe disease • Not a consensus stage-defining criterion
Surgical options• No fixed procedure-to-stage assignment is defined by the consensus staging table• No fixed procedure-to-stage assignment is defined by the consensus staging table• Surgical planning considers consensus stage, laterality, limbal involvement, visual-axis involvement, ocular-surface comorbidity, and disease cause • Options may include conjunctival-limbal autograft (CLAU), simple limbal epithelial transplantation (SLET), living-related conjunctival-limbal allograft (lr-CLAL), keratolimbal allograft (KLAL), cultivated limbal epithelial transplantation (CLET), or keratoprosthesis when clinically appropriate
Notes
  • • Consensus staging is based primarily on central 5-mm corneal involvement and the extent of limbal involvement. • The consensus does not define the original mild, moderate, and severe procedure-assignment table.

9. Differential Diagnosis

Conditions Mimicking LSCD

ConditionDifferentiating Feature
Corneal pannus (trachoma)• Fibrovascular superior corneal pannus • Trachomatous signs
Pterygium / Pseudopterygium• Pterygium: usually nasal • Pseudopterygium: may occur anywhere around the corneal periphery • Distinguish clinically by a plane of cleavage beneath its apex
Salzmann nodular degeneration• Nodular, grey-white • Subepithelial fibrocellular lesion with anterior stromal involvement
Superficial punctate keratopathy• Multiple causes • Epitheliopathy • A negative impression-cytology result for goblet cells does not exclude limbal stem cell deficiency
Recurrent corneal erosion• Epithelial adhesion defect with recurrent epithelial breakdown • Impression-cytology findings are not a definitive exclusion test for limbal stem cell deficiency
Neurotrophic keratopathy• Reduced corneal sensation and persistent epithelial defect • Impression cytology may show epithelial abnormalities or conjunctivalization • Findings are not absolute and should be interpreted with the clinical examination
Band keratopathy• Calcific deposits in the superficial cornea, including Bowman’s layer • Typically a horizontal grey-white band with relative peripheral clearing
Acne rosacea keratitis• Peripheral corneal inflammation or neovascularization • Often associated with blepharitis or meibomian gland dysfunction • May be bilateral • May progress to pannus, scarring or keratitis
Diagnostic Clincher: Key Differentiator
  • Impression cytology demonstrating goblet cells on the central cornea supports limbal stem cell deficiency; cytokeratin 19-positive cells may aid diagnosis but are not pathognomonic.
  • These findings support corneal conjunctivalization and limbal stem cell deficiency but do not distinguish limbal stem cell deficiency from all mimics; interpret them with the clinical examination and other diagnostic tests.
  • In vivo confocal microscopy showing absent palisades of Vogt supports limbal stem cell deficiency but does not independently confirm the diagnosis; correlate with clinical signs and other tests.

10. Medical Management

Principles of Medical Therapy

  • Medical management addresses:
  • (1) the underlying cause,
  • (2) ocular surface inflammation,
  • (3) tear film optimization,
  • (4) epithelial healing, and
  • (5) prevention of progression.
  • Mild limbal stem cell deficiency (LSCD) may respond to medical therapy alone; moderate-to-severe limbal stem cell deficiency (LSCD) may require surgical treatment when ocular-surface optimization and medical therapy are insufficient.
InterventionIndication / MechanismNotes
InterventionIndication / MechanismNotes
Preservative-free lubricants• Tear supplementation • Avoids preservative-associated ocular-surface toxicityCornerstone of all grades
Autologous serum (20–50%)• Epidermal growth factor, nerve growth factor, and fibronectin in serum • Promotes epithelial migration and proliferationUsed for persistent epithelial defect
Umbilical cord serum• Rich in growth factors • Alternative to autologous serumUseful when blood donation not possible
Scleral contact lenses• Promotes healing of persistent epithelial defects • Improves vision • Reduces pain and photophobiaSymptom control
Topical cyclosporin A (0.05–2%)• Anti-inflammatory • May aid control of ocular-surface inflammation
Topical corticosteroids (pulsed)Short-term treatment for ocular-surface inflammation • Avoid long-term use • Monitor intraocular pressure
Systemic doxycycline• Anti-matrix metalloproteinase • Anti-inflammatory • Reduces corneal meltingUseful in ocular rosacea-related limbal stem cell deficiency; the full combined indication remains incompletely verified
Systemic immunosuppression• Ocular cicatricial pemphigoid - dapsone, azathioprine, mycophenolate mofetil • Controls underlying autoimmune disease
Amniotic membrane transplantation• Anti-inflammatory • Basement-membrane scaffold that supports healing and re-epithelialization
Treatment of eyelid disease• Correct trichiasis, entropion, and lagophthalmos before limbal stem-cell transplantation • Optimize eyelid and ocular-surface health before transplantation
Neurotrophic keratopathy - Cenegermin• Recombinant human nerve growth factor • Promotes neurotrophic epithelial healing• United States Food and Drug Administration-approved • Oxervate (cenegermin 0.002%)
Topical insulin (0.5 units per drop)Promotes corneal epithelial healing; insulin and insulin-like growth factor signaling may contribute, but the precise mechanism remains incompletely establishedEmerging; evidence growing
Prosthetic Replacement of the Ocular Surface Ecosystem (PROSE)• Custom-fitted scleral device • Vaults the cornea and rests on the sclera • Filled with sterile saline to create a fluid reservoirSupports healing, symptom relief, and visual rehabilitation in complex ocular-surface disease
Additional management principles• Address and control concurrent ocular and systemic comorbidities before surgical management • Discontinue contact lens wear when it is the causative insult • Consider punctal occlusion for aqueous-deficient dry eye to stabilize the tear film before surgery

11. Surgical Management

Classification of Surgical Options

  • Common First Step: All limbal stem cell transplantation (LSCT) procedures share a common first step: removal of fibrovascular pannus from the cornea (superficial keratectomy / peeling) to expose stromal bed for re-epithelialization by transplanted cells.
ProcedureSourceIndicationLaterality of limbal stem cell deficiency (LSCD)
Conjunctival Limbal Autograft (CLAU)• Patient’s healthy fellow eye • Healthy residual limbus in the same eye• Commonly used for unilateral limbal stem cell deficiency (LSCD)• Primarily unilateral • Selected bilateral partial cases may be considered when sufficient healthy limbus remains
Simple Limbal Epithelial Transplantation (SLET)• Patient’s healthy fellow eye • Small limbal biopsy• Autologous simple limbal epithelial transplantation is primarily used for unilateral limbal stem cell deficiency (LSCD) • Allogeneic simple limbal epithelial transplantation may be used for bilateral disease • The small donor biopsy is intended to spare the donor eye• Primarily unilateral for autologous treatment • Bilateral disease may be considered with allogeneic treatment
Living Related Conjunctival Limbal Allograft (lr-CLAL)• Living related donor • Human leukocyte antigen (HLA) matching is preferred when available• Bilateral limbal stem cell deficiency (LSCD) with no adequate healthy autologous limbus• Bilateral
Keratolimbal Allograft (KLAL)• Deceased donor • Donor corneoscleral rim containing limbal tissue• Bilateral severe or total limbal stem cell deficiency (LSCD) • No suitable autologous or living-related donor tissue is available• Primarily bilateral • Selected cases may be considered when suitable autologous or living-related donor tissue is unavailable
Cultivated Limbal Epithelial Transplantation (CLET)• Patient limbus or donor tissue • Laboratory-expanded limbal epithelial cells• Selected unilateral or bilateral limbal stem cell deficiency (LSCD), including total disease • Ocular-surface status, donor tissue, and laboratory expansion must be suitable• Unilateral or bilateral
Cultivated Oral Mucosal Epithelial Transplantation (COMET)• Buccal mucosal biopsy • Cultured oral mucosal epithelial cells• Bilateral limbal stem cell deficiency (LSCD) • Suitable when an autologous oral mucosal epithelial source is preferred or suitable limbal donor tissue is unavailable• Bilateral
Keratoprosthesis (Boston Keratoprosthesis [KPro] or Osteo-odonto-keratoprosthesis)• Boston Keratoprosthesis (KPro): synthetic polymethyl methacrylate optic with polymethyl methacrylate or titanium support • Osteo-odonto-keratoprosthesis: autologous tooth-and-alveolar-bone support with a polymethyl methacrylate optical cylinder• End-stage corneal blindness or high-risk or failed corneal or limbal transplantation • Device selection depends on ocular-surface status • Type II keratoprosthesis or osteo-odonto-keratoprosthesis is considered for severe dry eye with a severely disrupted or keratinized surface• Often used for severe or end-stage disease • Frequently used in bilateral ocular-surface disorders • Individual-eye implantation is also possible, depending on device and clinical suitability

Prerequisites for limbal stem-cell transplantation (LSCT) - MUST CHECK ALL

  • Inflammation must be QUIESCENT (minimum 3–6 months quiet disease)
  • Eyelid abnormalities corrected (trichiasis, entropion, lagophthalmos)
  • Tear film optimized (treat aqueous deficiency, meibomian disease)
  • Clinically significant symblepharon released; conjunctival fornix reconstruction if needed
  • Systemic disease controlled; systemic immunosuppression optimized when indicated in ocular cicatricial pemphigoid (OCP)/Stevens–Johnson syndrome (SJS)
  • Recipient corneal stroma - assess vascularization and scarring
  • Endothelial function assessed - may need combined limbal stem-cell transplantation (LSCT) + penetrating/lamellar keratoplasty
  • Intraocular pressure (IOP) controlled - chronic topical medications may compromise the limbal epithelial stem-cell (LESC) niche

12. Conjunctival Limbal Autograft (CLAU)

Procedure & Anatomical Principles

  • First described by Kenyon & Tseng (1989).
  • Conjunctival limbal autograft (CLAU) harvests two grafts, each typically approximately 2–3 clock hours (60–90°), from the superior and inferior limbus of the contralateral healthy eye under peribulbar anaesthesia.
  • Each graft includes limbal epithelium, adjacent conjunctival tissue (commonly approximately 4–5 mm), and partial-thickness limbal tissue; the described technique removes approximately one-third thickness rather than specifying 0.5 mm of limbal stroma.
  • The grafts are sutured to the recipient cornea with 10/0 nylon, limbal end at the limbus.
  • In combined conjunctival limbal autograft (CLAU)–amniotic membrane transplantation procedures, amniotic membrane is placed over the recipient corneal and limbal defect before the conjunctival-limbal grafts are positioned.
  • Amniotic membrane is not obligatory for every conjunctival limbal autograft (CLAU) procedure.
Key Technical Points
Key Technical Points
AspectDetail
Harvest site• Commonly harvested from the superior (12 o’clock) and inferior (6 o’clock) limbus of the healthy contralateral eye
Graft size• Two donor grafts are commonly harvested • Typically about 2–3 clock hours per graft • Limit graft size and total donor-tissue harvest to reduce the risk of iatrogenic donor-eye limbal stem cell deficiency
Depth of harvest• Harvest a thin lamellar graft • Include conjunctiva, limbal tissue, and a sliver of superficial corneal stroma • Avoid specifying a fixed depth unless a technique-specific source is provided
Orientation• Maintain correct limbus-to-cornea polarity when suturing to the recipient • Align the limbal edge with the recipient limbus
Amniotic membrane• In combined conjunctival limbal autograft–amniotic membrane transplantation, amniotic membrane may be placed over the recipient ocular surface as an adjunct • Supports epithelial healing • Has anti-inflammatory properties
Sutures• Secure grafts with interrupted 10/0 nylon sutures • Fibrin tissue adhesive is an alternative
Donor eye• Use a healthy contralateral eye or an eye with adequate healthy residual limbus • Excessive harvest may cause iatrogenic donor-eye limbal stem cell deficiency

Advantages & Disadvantages

Advantages & Disadvantages
Advantages & Disadvantages
AdvantagesDisadvantages
• No immunosuppression required (autologous)• Requires a healthy autologous limbal donor source • Usually the contralateral eye
• Excellent long-term success (70–80%)• Risk of inducing limbal stem cell deficiency in the donor eye through over-harvesting
• Technically straightforward• Generally unsuitable for bilateral total limbal stem cell deficiency when no healthy autologous donor limbus is available
• No human leukocyte antigen matching needed• Limited donor tissue constrains the amount of limbus that can be harvested
• Single-stage procedure• Learning curve for surgical harvest technique
Surgical warning
  • Limit harvested limbal tissue according to the surgical technique and donor-eye safety.
  • Published donor-site data support harvesting 2 clock-hours superiorly and 2 clock-hours inferiorly in carefully selected healthy donor eyes.
  • Donor-eye limbal stem cell deficiency is a recognized potential complication of conjunctival limbal autograft harvesting.
  • Other donor-site complications include filamentary keratitis, subconjunctival hemorrhage, epithelial abnormalities, and scarring.

13. Simple Limbal Epithelial Transplantation (SLET)

Concept & Rationale (Sangwan et al., 2012)

  • Simple limbal epithelial transplantation (SLET) was first described in 2012 by Virender S. Sangwan and colleagues at the L V Prasad Eye Institute; Harminder Dua was not an author of the original report.
  • It uses a 2 × 2 mm strip of limbal tissue from the healthy fellow eye, divides it into eight to ten small pieces, and distributes the pieces epithelial-side up over an amniotic membrane covering the recipient cornea, typically securing the membrane and tissue pieces with fibrin glue - all in one surgical operation.
FeatureSimple Limbal Epithelial Transplantation (SLET)Cultivated Limbal Epithelial Transplantation (CLET)
Lab requirement• Single-stage procedure • No specialist laboratory for ex vivo cell expansion• Limbal biopsy followed by ex vivo culture and expansion • Later transplantation stage • Culture commonly requires approximately 2–3 weeks • Laboratory requirements vary by protocol and regulatory setting
Biopsy size• Approximately 2 × 2 mm limbal strip in the original report • About 4 mm²• Approximately 1 mm² biopsy in the original report • Dimensions vary among protocols
Procedure time• Single-stage procedure • Operative duration is protocol- and case-dependent • Approximately 60–90 minutes is not established here• Staged procedure • Limbal biopsy, ex vivo culture and expansion, then later transplantation
Cost• Lower cost • Avoids ex vivo cell culture • Avoids a second transplantation procedure• Higher cost • Requires specialised cell-culture infrastructure • Requires consumables and trained personnel
Availability• Does not require a specialist laboratory for ex vivo cell expansion • Requires appropriate ocular-surface surgical expertise • Requires donor-tissue handling and postoperative care• Generally requires access to a specialised cell-culture laboratory
Success rates• Do not use a universal rate • Estimates vary by outcome definition, follow-up, case mix, and study design • Quote the specific outcome measure and source when reporting a rate• Do not use a universal rate • Estimates vary by outcome definition, follow-up, case mix, and study design • Quote the specific outcome measure and source when reporting a rate
Disadvantage• Autologous treatment generally requires a healthy donor limbus • Autologous treatment is intended for unilateral limbal stem cell deficiency • Allogeneic treatment may be considered in bilateral limbal stem cell deficiency • Allogeneic treatment requires immunosuppression• Ex vivo culture and laboratory dependence • Increased cost • Possible manufacturing or culture failure
Immunosuppression• Autologous Simple Limbal Epithelial Transplantation (SLET): systemic immunosuppression generally not required • Allogeneic Simple Limbal Epithelial Transplantation (SLET): systemic immunosuppression required• Autologous Cultivated Limbal Epithelial Transplantation (CLET): systemic immunosuppression generally not required • Allogeneic Cultivated Limbal Epithelial Transplantation (CLET): systemic immunosuppression required
FeatureSimple limbal epithelial transplantation (SLET)Cultivated limbal epithelial transplantation (CLET)
Lab requirement• No specialist cell-culture laboratory • Single-stage procedure• Cell-culture laboratory • Approximately 2–3 weeks of ex vivo culture
Biopsy size• Approximately 2 × 2 mm in the original report • About 4 mm²• Small limbal biopsy • Dimensions vary by protocol, including approximately 1 × 2 mm and 1.5 × 2.5 × 0.25 mm specimens
Procedure time• Single-stage procedure • Operative time not specified here• Two-stage process • Biopsy, ex vivo culture, and later transplantation
Cost• Lower cost • Avoids ex vivo cell culture and a second transplantation procedure • Uses amniotic membrane and fibrin glue• Higher cost • Cell-culture costs and an additional transplantation stage
Availability• Does not require a specialist cell-culture laboratory • Requires appropriate ocular-surface surgical expertise, donor-tissue handling, and postoperative care• Generally requires access to a specialized cell-culture laboratory
Success rates• Do not use a universal rate here • Published estimates vary by outcome definition, follow-up, case mix, and study design• Do not use a universal rate here • Published estimates vary by outcome definition, follow-up, case mix, and study design
Disadvantage• Autologous simple limbal epithelial transplantation (SLET) generally requires a healthy donor limbus and is intended for unilateral limbal stem cell deficiency (LSCD) • Allogeneic simple limbal epithelial transplantation (SLET) may be considered in bilateral limbal stem cell deficiency (LSCD) but requires immunosuppression• Ex vivo culture and laboratory dependence • Additional cost • Possible manufacturing or culture failure
Immunosuppression• Generally not required for autologous simple limbal epithelial transplantation (SLET) • Commonly used for allogeneic simple limbal epithelial transplantation (SLET)• Generally not required for autologous cultivated limbal epithelial transplantation (CLET) • Commonly used for allogeneic cultivated limbal epithelial transplantation (CLET)
SLET - Surgical Steps
  1. Superficial keratectomy - remove fibrovascular pannus from corneal surface
  2. Amniotic membrane (AM) suturing/fibrin glue to denuded corneal stroma (basement membrane side up)
  3. Harvesting of a 2 × 2 mm strip of donor limbal tissue from the healthy eye
  4. Biopsy divided into 8–10 small pieces using Vannas scissors
  5. Pieces distributed over the amniotic membrane (AM) surface in a circular or concentric pattern, avoiding the visual axis
  6. Fibrin glue applied to fix fragments to the amniotic membrane (AM)
  7. Bandage contact lens applied; postoperative topical antibiotics and corticosteroids are commonly used, and artificial tears may support epithelial healing
  8. Fragments act as in-vivo expansion substrates - epithelium proliferates and migrates from each fragment, with epithelial islands eventually coalescing
Exam pearl
  • Simple limbal epithelial transplantation (SLET) science
  • Simple limbal epithelial transplantation (SLET) mirrors cultivated limbal epithelial transplantation (CLET) but performs in-vivo expansion instead of ex-vivo expansion.
  • Amniotic membrane has anti-inflammatory properties, including tumour necrosis factor-stimulated gene 6 expression.
  • Amniotic-membrane stromal matrix can increase interleukin-1 receptor antagonist expression in cultured limbal epithelial cells.
  • Amniotic membrane provides a basement-membrane scaffold containing laminin and fibronectin.
  • Amniotic membrane provides growth factors, including epidermal growth factor (EGF) and transforming growth factor beta (TGF-beta).
  • Simple limbal epithelial transplantation (SLET) is a practical option in resource-limited settings because it avoids specialised ex-vivo cell-culture facilities.

14. ALLOGENEIC LSCT - lr-CLAL & KLAL

Living Related Conjunctival Limbal Allograft (lr-CLAL)

  • For bilateral limbal stem cell deficiency (LSCD).
  • A best-matched first-degree relative, commonly a sibling or parent, may donate limbal-conjunctival tissue; donor selection and graft extent follow the relevant surgical protocol.
  • Potential advantages include use of a living related donor and the possibility of donor-recipient matching.
  • Disadvantage: potential harm to healthy donor eye; requires systemic immunosuppression.

Keratolimbal Allograft (KLAL)

  • Uses cadaveric corneoscleral rims preserved in appropriate storage medium and implanted within 5 days of donor death.
  • Two donor rims (one eye each) provide ~360° of limbal tissue arranged circumferentially on recipient.
  • Provides maximum limbal epithelial stem-cell (LESC) density but highest alloimmune risk.
FeatureLiving-related conjunctival-limbal allograft (lr-CLAL)Keratolimbal allograft (KLAL)
• Donor• Living related (human leukocyte antigen-matched)• Cadaveric (eye bank)
• Tissue viability• Maximum (fresh)• Good if < 5 days
• Human leukocyte antigen matching• Feasible and preferred• Matching considerations differ for cadaveric keratolimbal allograft.
• Limbal epithelial stem-cell (LESC) quantity• Moderate (< 360°)• Maximum (360° possible)
• Immunosuppression• Systemic required• Systemic required; the regimen and duration should be individualized according to rejection risk and clinical course.
• Donor eye risk• Yes (similar to conjunctival-limbal autograft risk)• None
• Cost• Moderate• Eye bank cost; processing fees
• Success rate (5-year)• ~40–60%• ~30–50% (lower due to mismatch)
• Best indication• Bilateral limbal stem cell deficiency; suitable relative• Bilateral limbal stem cell deficiency; no suitable living donor
Immunosuppression Protocol for Allogeneic LSCT
Immunosuppression Protocol for Allogeneic LSCT
AgentDoseDurationMonitoring
Prednisone (systemic)• 1 mg/kg/day initially • Then taper according to ocular-surface stability• Taper duration individualized to ocular-surface stability and the immunosuppressive regimen• Blood pressure, glucose, and bone density monitoring
Cyclosporine A• 3–5 mg/kg/day • Target blood level: 100–200 ng/mL• Several years may be required • Duration individualized according to ocular-surface stability, graft status, and systemic adverse effects • May be prolonged or indefinite• Renal function • Liver function tests • Blood pressure
Mycophenolate mofetil• 1 g twice daily (2 g/day) • Regimen selection and combination therapy individualized• Duration individualized • Prolonged therapy may be required • Reported mean: 52.7 months; range: 23–91 months in one keratolimbal allograft series• Complete blood count • Liver profile
Topical cyclosporine• May be added as required • Concentration and dosing are regimen-specific• Duration individualized according to ocular-surface inflammation and the postoperative regimen• Monitor ocular-surface tolerance • Monitor intraocular pressure during concomitant topical corticosteroid therapy
Topical steroids• Taper according to ocular-surface stability and steroid response • Continue at an individualized maintenance dose when indicated• Taper duration individualized to ocular-surface stability and steroid response• Intraocular-pressure monitoring
Exam pearl
  • Critical Distinction: Rejection vs. Failure in limbal stem cell transplantation (LSCT):
  • Rejection = immune-mediated attack on allograft.
  • Associated findings may include acute inflammation, neovascularization ingrowth, and epithelial breakdown.
  • Treat with pulse steroids and cyclosporin A.
  • Primary failure = graft never established epithelialization.
  • Late failure = later partial or total loss of a previously established epithelial surface, often associated with chronic rejection and may include recurrent conjunctivalization.

15. Cultivated Limbal Epithelial Transplantation (CLET)

  • A 1–2 mm² limbal biopsy is expanded ex vivo for approximately 2–3 weeks on various substrates to generate a sheet enriched for limbal epithelial stem cells. Good Manufacturing Practice (GMP) conditions are used in validated manufacturing protocols.
  • The cultivated sheet is then transplanted onto the denuded recipient cornea.
Culture Substrates Used for CLET
Culture Substrates Used for CLET
SubstratePropertiesCurrent Status
Amniotic membrane (denuded)• Natural basement membrane • Contains collagen IV and laminin • Anti-inflammatory and immunomodulatory properties• Most commonly used clinically as a human amniotic-membrane substrate for cultivated limbal epithelial transplantation (CLET)
Fibrin gel• Biodegradable and absorbable • Clear supportive layer in Holoclar • Xenogeneic-free status depends on the formulation• Used in Europe for Holoclar
Temperature-responsive poly(N-isopropylacrylamide)• Supports intact epithelial cell-sheet engineering • Harvested graft is carrier-free • Retains deposited extracellular matrix • No scaffold remains in the graft• Research and translation • Developed in Japan for temperature-responsive carrier-free epithelial cell sheets, including corneal and oral mucosal epithelial sheets
Collagen / gelatin scaffolds• Biomimetic or niche-mimicking three-dimensional support • Structural and biomechanical support for limbal epithelial growth• Research phase • Experimental biomaterials evaluated in vitro or in preclinical tissue-engineering models
Decellularized cornea• Preserves native extracellular-matrix architecture when appropriately processed • Can retain good optical transparency• Experimental or research-stage substrate for cultivated limbal epithelial transplantation (CLET)
Human amniotic membrane (HAM)• Human-derived amniotic tissue • Commonly used as a substrate for cultivated limbal epithelial transplantation (CLET) • Xenogeneic-free status depends on the complete manufacturing and culture formulation• Commonly used clinically • Deepithelialized human amniotic membrane is often preferred for limbal epithelial growth

HOLOCLAR - Advanced Therapy Medicinal Product for Ocular Disease (European Union Marketing Authorisation, 2015)

  • Landmark - Holoclar: Holoclar (Holostem s.r.l., Modena, Italy) is an Advanced Therapy Medicinal Product (ATMP) authorised for use in the European Union for treating adults with moderate-to-severe limbal stem cell deficiency (LSCD) due to ocular burns, including physical and chemical burns.
  • It uses autologous limbal cells cultured on fibrin substrate.
  • Selection criterion: p63bright cells > 3% in final product = quality marker for transplant adequacy.
Quality Criteria for CLET Product
Quality Criteria for CLET Product
ParameterAcceptable RangeSignificance
p63-bright cells> 3% of total cells• Associated with successful limbal stem-cell transplantation. • Not sufficient alone to ensure success.
Viability> 80%• Ensures adequate live cells for engraftment.
SterilityNo contamination• Sterility testing/no microbial growth is controlled within the validated Good Manufacturing Practice (GMP) quality system. • Exact acceptance criteria are protocol-specific.
Mycoplasma testingNegative• Safety: negative mycoplasma testing helps detect mycoplasma contamination. • It does not by itself exclude all feeder-layer contamination or feeder-cell-associated risks.
Cytokeratin 3 (CK3) / cytokeratin 12 (CK12)Present• Supports a corneal epithelial phenotype. • Phenotypic characterization.
Cytokeratin 19 (CK19)No universal threshold established• Interpret with other phenotypic markers. • Cytokeratin 19 (CK19) alone does not exclude conjunctival contamination.

16. Surgical Decision-Making Algorithm

Step-by-Step Decision Framework

Step-by-Step Decision Framework
Step-by-Step Decision Framework
StepDecision PointRecommendation
STEP 1Establish Diagnosis & Grade• Impression cytology: conjunctival-type cells identified with more specific markers such as cytokeratin 7 (CK7), cytokeratin 13 (CK13), or mucin 5AC (MUC5AC), with or without goblet cells, support limbal stem cell deficiency (LSCD) assessment. • Findings are adjunctive. • Goblet cells may be absent. • In vivo confocal microscopy (IVCM): assess limbal architecture, including possible palisades of Vogt loss. • Do not use in vivo confocal microscopy (IVCM) as a standalone diagnostic or severity criterion. • Anterior-segment optical coherence tomography (AS-OCT): complementary assessment of epithelial and limbal/corneal structural changes. • Do not use anterior-segment optical coherence tomography (AS-OCT) as a standalone grading test. • Use clinical staging: Stage I–III. • Stage I is subdivided into A, B, and C. • Do not use an unqualified Grade I–IV scale.
STEP 2Establish Laterality• Unilateral limbal stem cell deficiency (LSCD) → consider autologous options first when the fellow eye has adequate healthy limbal reserve. • Bilateral limbal stem cell deficiency (LSCD) → usually requires an allogeneic or cultivated approach. • Select according to residual limbal tissue, etiology, ocular-surface/adnexal status, visual-axis involvement, and suitability for systemic immunosuppression.
STEP 3Optimize Ocular Surface• Control ocular-surface inflammation and optimize the surface before limbal stem cell transplantation (LSCT). • In significant inflammatory disease, aim for a clinically quiet surface for several months, commonly at least 3 months, before surgery. • Treat eyelid and adnexal disease. • Optimize the tear film. • Manage symblepharon or fornix abnormalities before limbal stem cell transplantation (LSCT) when they compromise epithelial healing.
STEP 4Assess Fellow Eye• If normal and with adequate healthy limbal reserve → conjunctival limbal autograft (CLAU) or simple limbal epithelial transplantation (SLET) may be considered as autologous options. • If compromised or unable to provide an adequate graft → consider cultivated limbal epithelial transplantation (CLET) using selected residual healthy limbus or allogeneic limbal stem cell transplantation (LSCT), according to disease extent and ocular-surface status.
STEP 5For Bilateral Limbal Stem Cell Deficiency (LSCD)• Suitable living relative, preferably the best available human leukocyte antigen (HLA)-matched relative? → consider living-related conjunctival limbal allograft (lr-CLAL) after assessing donor suitability, surface status, and immunosuppression requirements. • No suitable living relative? → consider keratolimbal allograft (KLAL), with attention to donor-tissue availability and suitability for systemic immunosuppression. • Want to reduce donor-eye risk? → consider cultivated limbal epithelial transplantation (CLET) using a small biopsy. • In selected partial limbal stem cell deficiency (LSCD), an autologous biopsy may be obtained from healthy residual limbus in the affected eye. • Donor risk is reduced, not eliminated.
STEP 6Assess Corneal Stroma• Clear stroma → limbal stem cell transplantation (LSCT) alone may be appropriate when the ocular surface and adnexa are otherwise suitable and there is no visually significant stromal opacity. • Stromal scarring or visually significant opacity → consider limbal stem cell transplantation (LSCT) with lamellar or penetrating keratoplasty. • Perform sequentially or simultaneously according to the clinical situation. • A staged approach is generally preferred when feasible. • Severe scarring with failed limbal stem cell transplantation (LSCT) → consider keratoprosthesis selectively, depending on ocular-surface stability, adnexal status, visual potential, and systemic disease.
STEP 7Post-operative Management• Autologous: use topical corticosteroid after surgery with an individualized taper. • Use lubricants as needed. • Allogeneic: use individualized systemic immunosuppression - commonly a corticosteroid plus a calcineurin inhibitor such as ciclosporin (CsA) or tacrolimus, with mycophenolate mofetil (MMF) used in selected protocols. • Use topical therapy and specialist coordination. • Monitor for graft rejection, epithelial healing, and surface stability. • When systemic immunosuppression is used, monitor immunosuppressive dosing, blood counts, blood glucose, and liver and kidney function.

Quick Reference - Procedure Selection Matrix

Clinical ScenarioRecommended Procedure
Unilateral limbal stem cell deficiency; normal fellow eye; any stage• Conjunctival-limbal autograft or autologous simple limbal epithelial transplantation. • Consider autologous cultivated limbal epithelial transplantation where appropriate.
Unilateral limbal stem cell deficiency; prefer minimal donor harvest• Simple limbal epithelial transplantation (2 × 2 mm biopsy). • Autologous cultivated limbal epithelial transplantation.
Bilateral limbal stem cell deficiency; human leukocyte antigen-matched sibling available• Consider living-related conjunctival-limbal allograft. • Use individualized systemic immunosuppression according to human leukocyte antigen matching and rejection risk.
Bilateral limbal stem cell deficiency; no suitable live donor• Keratolimbal allograft or allogeneic simple limbal epithelial transplantation plus systemic immunosuppression. • Consider autologous cultivated limbal epithelial transplantation only if adequate healthy residual limbus remains.
Bilateral limbal stem cell deficiency; total (360°); no limbus• Consider cultivated oral mucosal epithelial transplantation or allogeneic limbal stem cell transplantation when appropriate. • Reserve keratoprosthesis for selected end-stage disease according to tear function and adnexal status.
Aniridia limbal stem cell deficiency (bilateral, total)• Living-related conjunctival-limbal allograft or keratolimbal allograft. • Guarded prognosis due to persistent paired box gene 6 (PAX6) defect.
Stevens–Johnson syndrome / ocular cicatricial pemphigoid (bilateral; severe dry eye)• Optimize ocular-surface and systemic disease control. • Consider Boston keratoprosthesis Type II or modified osteo-odonto-keratoprosthesis in selected end-stage cases.
Chemical burn (unilateral)• Conjunctival-limbal autograft or autologous simple limbal epithelial transplantation when the fellow eye has adequate healthy limbal reserve. • Bilateral disease or inadequate fellow-eye reserve: consider allogeneic limbal stem cell transplantation, including allogeneic cultivated limbal epithelial transplantation, with systemic immunosuppression as appropriate.
Failed limbal stem-cell transplantation + dense stromal scarring• Keratoplasty after ocular-surface stabilisation. • Keratoprosthesis or modified osteo-odonto-keratoprosthesis in selected end-stage cases.
Limbal stem cell deficiency + endothelial failure• Stabilize the ocular surface with limbal stem-cell transplantation. • Then consider endothelial keratoplasty or penetrating keratoplasty according to the corneal pathology. • Use a staged approach when appropriate.

17. Keratoprosthesis in End-Stage LSCD

Boston keratoprosthesis in limbal stem cell deficiency (LSCD)

  • In selected eyes with end-stage bilateral limbal stem cell deficiency (LSCD) and poor-prognosis ocular-surface disease:
  • Keratoprosthesis may be considered when limbal or corneal reconstruction has failed, is contraindicated, or is unlikely to succeed.
  • Keratoprosthesis provides an artificial optical pathway bypassing the failed ocular surface.
  • A sufficiently wet ocular surface is important for Boston type I implantation.
TypeIndication in limbal stem cell deficiency (LSCD) contextKey features
Boston keratoprosthesis Type I• End-stage limbal stem cell deficiency (LSCD) with poor prognosis for conventional keratoplasty • Prior ocular-surface reconstruction may have failed or be unlikely to succeed • Sufficiently wet ocular surface • Adequate eyelid closure and postoperative care are important• Retained donor corneal carrier • Used for selected limbal stem cell deficiency (LSCD) with a sufficiently wet ocular surface
Boston keratoprosthesis Type II• Stevens–Johnson syndrome (SJS) • Ocular cicatricial pemphigoid (OCP) • Severe dry eye • Severe cicatrizing ocular-surface disease• Anterior optical component protrudes through a permanent tarsorrhaphy
Osteo-odonto-keratoprosthesis (OOKP)• End-stage corneal blindness • Severe dry eye or damaged ocular surface • No other treatment likely to restore sight• Patient’s own tooth root and alveolar bone • Synthetic optical cylinder • High anatomical retention rates
AlphaCor• Alternative for selected eyes at high risk of conventional corneal graft failure • Requires a sufficiently wet ocular surface• Cross-linked poly(2-hydroxyethyl methacrylate) (poly(HEMA)) hydrogel • Distinct skirt and optic components • Skirt designed for tissue integration within host corneal tissue
KeraKlear / MICROKPRO• KeraKlear: investigational or emerging clinical option• KeraKlear: foldable, nonpenetrating artificial cornea • Implanted into a lamellar or intrastromal corneal pocket • Additional features for MICROKPRO remain unresolved
Exam pearl
  • OOKP - Surgical Genius: Osteo-odonto-keratoprosthesis (OOKP) Pearl:
  • Osteo-odonto-keratoprosthesis (OOKP) was associated with Strampelli in 1963 and later modified by Falcinelli.
  • Osteo-odonto-keratoprosthesis (OOKP) uses the patient's own canine or premolar tooth root with surrounding alveolar bone as a biological carrier for the optical cylinder.
  • The lamina is implanted in a subcutaneous or submuscular pouch in the orbitozygomatic/periorbital region for approximately 3 months to allow revascularization and connective-tissue coverage, then transferred to the anterior surface of the globe with buccal mucosal cover.
  • Reported 10-year anatomical survival is approximately 66–67% in large retrospective series.

18. Landmark Trials & Evidence Base

StudyAuthors / YearProcedureKey Finding
Pellegrini et al.Pellegrini G, 1997 LancetCultivated limbal epithelial transplantation• First reported successful reconstruction of the ocular surface using autologous cultivated limbal/corneal epithelium • Proof of concept for cultivated limbal epithelial transplantation
Rama et al.Rama P et al., 2010 New England Journal of MedicineAutologous cultivated limbal epithelial transplantation• p63-bright cells >3% predicted treatment success • 78% success when p63-bright cells exceeded 3% versus 11% when they were ≤3% • Permanent restoration in 76.6% of eyes • Follow-up extended up to 10 years
Simple limbal epithelial transplantation introductionSangwan VS et al., 2012 British Journal of OphthalmologySimple limbal epithelial transplantation• First description of simple limbal epithelial transplantation • Complete epithelialisation and a stable avascular corneal surface in 6/6 eyes (100%) by 6 weeks • Visual acuity improved to 20/60 or better in 4/6 eyes (66.6%) • Single-stage procedure; no specialist laboratory was required for cell expansion
Conjunctival limbal autograft clinical seriesKenyon KR, Tseng SC, 1989 OphthalmologyConjunctival limbal autograft• Clinical series of limbal autograft transplantation for ocular-surface disorders • Recommended for widespread ocular-surface damage with limbal epithelial stem-cell loss, including chemical or thermal burns, contact lens-induced keratopathy, and selected persistent epithelial defects • Stable epithelial adhesion in 20/21 cases (95%) • Rapid surface healing in 19/21 cases (90%) • Visual acuity improved in 17/21 cases (81%)
Nishida et al. 2004 New England Journal of MedicineNishida K et al., 2004 New England Journal of MedicineCultivated oral mucosal epithelial transplantation• Tissue-engineered cell sheets composed of autologous oral mucosal epithelial cells • Oral mucosal epithelium was a viable alternative for ocular-surface reconstruction • No limbal tissue was required
Cenegermin (Oxervate)REPARO trial - Bonini S et al., 2018 OphthalmologyTopical recombinant human nerve growth factor• REPARO evaluated topical recombinant human nerve growth factor for moderate-to-severe neurotrophic keratitis • Cenegermin (Oxervate) is approved for neurotrophic keratitis • Its use in limbal stem cell deficiency is outside the approved indication and remains investigational

19. Emerging Therapies & Future Directions

Frontier Approaches in Limbal Stem Cell Deficiency (LSCD) Management

ApproachDescription
Induced Pluripotent Stem Cell (iPSC) - Derived Corneal Epithelium• First-in-human allogeneic induced pluripotent stem cell (iPSC)-derived corneal epithelial cell-sheet transplantation reported in Japan by Soma et al., Lancet 2024; four eyes. • Well tolerated over two years, with clinical improvement reported during follow-up. • Larger clinical trials are needed.
Three-Dimensional (3D) Bioprinting of Limbal Niche• Experimental bioprinting has produced corneal and limbal constructs, including printed epithelium-mimicking structures containing human embryonic stem-cell-derived limbal epithelial stem cells using collagen I/laminin-based bioinks. • Separate studies have encapsulated limbal stem cells in gelatin methacryloyl (GelMA)-based hydrogel scaffolds. • Experimental niche models are intended to replicate the biomechanical environment of native limbal tissue. • Pre-clinical phase.
Gene Therapy for Paired Box 6 (PAX6) in Aniridia-Associated Limbal Stem Cell Deficiency (LSCD)• Adeno-associated virus (AAV)-mediated paired box 6 (PAX6) gene augmentation is a proposed/preclinical strategy to restore or support limbal epithelial stem-cell specification. • Preclinical studies in aniridia models are underway; a Phase I paired box 6 (PAX6) trial associated with Trefoil Therapeutics was not established by the reviewed sources. • If successful, this approach might support or delay the need for transplantation, but it has not been shown to eliminate transplantation requirements.
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 Correction of Ectrodactyly, Ectodermal Dysplasia, and Cleft Lip/Palate (EEC) / Keratitis-Ichthyosis-Deafness (KID) Syndrome• Ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein-based editing of tumor protein p63 (TP63)-associated ectrodactyly, ectodermal dysplasia, and cleft lip/palate (EEC) patient-derived epithelial or limbal-related cells has been proposed and studied experimentally before regenerative transplantation. • Equivalent correction of gap junction beta 2 (GJB2) mutations in keratitis-ichthyosis-deafness (KID)-syndrome limbal epithelial stem cells was not established by the reviewed sources. • A combined gene-therapy and cultivated limbal epithelial transplantation (CLET) strategy remains a research approach.
Nanoparticle Drug Delivery to the Limbal Niche• Nanoparticle-based ocular-surface delivery of anti-inflammatory agents is an experimental approach in limbal stem cell deficiency (LSCD)-related corneal injury. • Targeted delivery of anti-vascular endothelial growth factor (VEGF) agents or growth factors directly to the limbus has not been established by the reviewed sources. • Reduction of the requirement for systemic immunosuppression remains unproven.
Decellularized Corneal Matrix as a Cultivated Limbal Epithelial Transplantation (CLET) Substrate• Decellularized human corneal or limbal scaffolds are being investigated experimentally as biomimetic, potentially non-immunogenic substrates for recellularization with limbal epithelial progenitor cells. • Their use as established xeno-free cultivated limbal epithelial transplantation (CLET) scaffolds has not been clinically established. • Experimental studies report preservation or restoration of optical transmission and selected mechanical properties. • Superiority in transparency and biomechanical compatibility over amniotic membrane has not been directly demonstrated.
Exosome Therapy• Human limbal epithelial cell-derived exosomes contain microRNA and protein cargos and can enhance wound healing in cultured limbal stromal cells. • Exosome-based topical therapy is an investigational cell-free alternative for limbal stem cell deficiency (LSCD) management. • Active research area, with evidence mainly from in-vitro and animal studies.
Umbilical Cord Blood-Derived Stem Cells• Umbilical-cord-derived mesenchymal stem cells, including Wharton's-jelly-derived mesenchymal stromal cells (MSCs), are being investigated for anti-inflammatory and limbal-niche-modulating paracrine effects. • These effects remain experimental in limbal stem cell deficiency (LSCD). • Local administration of umbilical-cord-derived mesenchymal stromal cells or conditioned medium has promoted corneal epithelial wound healing and altered limbal-niche markers in animal models. • Direct evidence that subconjunctival injection specifically promotes limbal epithelial stem-cell survival is limited.
Artificial Intelligence-Assisted In Vivo Confocal Microscopy (IVCM) Analysis• Deep-learning algorithms have been evaluated on in vivo confocal microscopy (IVCM) images for corneal nerve-morphology analysis and experimental limbal stem cell deficiency (LSCD) detection. • Experimental models have classified limbal stem cell deficiency (LSCD) across disease stages using nerve-morphology features. • Automated palisades-of-Vogt loss detection, validated early grading, and treatment-response monitoring have not been established. • Clinical validation for these broader applications remains unestablished by the reviewed sources.

20. High-Yield MCQ Traps & Viva Questions

MCQ Traps - Consultant Level

MCQ

Q1. A patient with unilateral chemical burn limbal stem cell deficiency (LSCD) undergoes conjunctival limbal autograft (CLAU) from the contralateral eye. Which is a serious potential donor-eye complication?

MCQ

Q2. Which marker on corneal impression cytology identifies conjunctival goblet cells in limbal stem cell deficiency (LSCD)?

MCQ

Q3. Holoclar received European Medicines Agency (EMA) approval in 2015. What is the quality-control marker associated with its success?

MCQ

Q4. A patient with Stevens–Johnson syndrome has bilateral total limbal stem cell deficiency with severe aqueous deficiency, keratinized lid margins, and inability to fully close the eyes. Which listed option is specifically designed for severe dry eye with inability to close the lids?

MCQ

Q5. In simple limbal epithelial transplantation (SLET), small limbal fragments are placed on amniotic membrane. What is the PRIMARY mechanism by which epithelium covers the cornea?

MCQ

Q6. Aniridia-related limbal stem cell deficiency (LSCD) has a specific molecular basis. Which gene mutation causes it, and what does it regulate?

MCQ

Q7. A 35-year-old with bilateral alkali burn undergoes keratolimbal allograft. At 6 months, re-conjunctivalization occurs acutely with inflammatory features. This is best classified as:

MCQ

Q8. Which of the following is MOST CHARACTERISTIC of limbal stem cell deficiency (LSCD) on slit-lamp examination?

21. Viva Follow-Up Questions

Oral-exam Q&A
Q1

Why does LSCD from alkali burn have a poorer prognosis than acid burn, despite both causing LSCD?

Oral-exam Q&A
Q1

In a patient with Grade III LSCD undergoing KLAL, at what time point would you consider performing a penetrating keratoplasty, and why?

VIVA FOLLOW-UP QUESTIONS
Q1

What is the significance of the sub-basal nerve plexus (SBNP) in LSCD, and how do you assess it?

VIVA FOLLOW-UP QUESTIONS
Q1

How does CLET in aniridia differ from post-burn LSCD, and what are the implications for gene therapy?

22. Advanced Consultant-Level Extension Question

Consultant-level oral-exam question

A 28-year-old woman presents with bilateral aniridia (PAX6 heterozygous mutation, confirmed by genetic testing). She has Grade III LSCD in the right eye (> 6 clock hours conjunctivalized, moderate central opacity, superficial NV) and Grade I LSCD in the left (< 3 clock hours limbal loss, central cornea clear). Her left eye has BCVA of 6/9. Her HLA-matched older brother is willing to donate. Systemic examination is otherwise normal. (a) Outline your surgical management strategy for her RIGHT eye, including your choice of LSCT procedure and rationale. (b) Why would CLET using her OWN left eye limbal biopsy be suboptimal in this case, despite the left eye appearing relatively preserved? (c) If she proceeds with lr-CLAL from her brother, what are the implications of using PAX6 haploinsufficient donor cells for long-term outcomes, and how would your counselling differ compared to a post-burn bilateral LSCD patient? (d) A Phase I gene therapy trial with AAV-PAX6 is recruiting. She asks if she should enrol. How would you counsel her, integrating both current surgical options and emerging therapy?

Was this helpful?

Topic complete

Continue to another topic when you are ready.

Previous topic← Post Refractive EctasiaNext topicSimple Limbal Epithelial Transplantation (SLET)